What Is Compound Heterozygous in Genetics?

Compound heterozygous describes a person who carries two different mutations in the same gene, one on each copy of the chromosome. Because humans inherit one copy of most genes from each parent, a compound heterozygous individual has received a different defective version from each parent, which can knock out the gene’s function entirely. This pattern is distinct from being homozygous for a single mutation (two identical copies of the same error) and has become increasingly important in diagnosing rare diseases and predicting how severe a condition will be.

How Two Different Mutations End Up in One Person

Every person carries two copies of each gene (except for genes on the sex chromosomes in males). When both copies carry the exact same mutation, that person is homozygous for that mutation. But sometimes a person inherits one mutation from their mother and a completely different mutation in the same gene from their father. That person is compound heterozygous. Each parent contributed a working copy of the gene alongside their broken one, so neither parent is affected. But the child, unlucky enough to receive two different broken versions, may have no working copy left at all.

This matters most for recessive conditions, where you need both copies of a gene to be non-functional before symptoms appear. When geneticists first studied recessive diseases, they focused on families where the same mutation ran through both sides. Compound heterozygosity was harder to spot because each parent carried a different variant, and neither showed up in a standard family history as an obvious match. As gene sequencing has become cheaper and more thorough, compound heterozygosity has turned out to be common in recessive disease, sometimes more common than homozygosity for any single mutation.

Why “In Trans” Versus “In Cis” Changes Everything

If you find two different mutations in someone’s gene, you still do not know whether they are truly compound heterozygous until you figure out which chromosome each mutation sits on. Geneticists call this “phasing.” The two possible arrangements are called “in trans” and “in cis.” In trans means each mutation sits on a different chromosome, so both copies of the gene are damaged. In cis means both mutations landed on the same chromosome, leaving the other chromosome’s copy of the gene perfectly intact. Only the in-trans arrangement causes disease in a recessive pattern, because only then are both gene copies knocked out.¹

This distinction is not academic. A study of filaggrin gene mutations, which are linked to skin barrier disorders and eczema, examined 37 people who carried two different null mutations. Every single one of them turned out to carry the mutations in trans, making them functionally equivalent to homozygous individuals with no working filaggrin gene at all.² Had those mutations been in cis instead, those individuals would have had one fully functional gene copy and likely far milder or no symptoms.

Determining phase is one of the trickiest parts of genetic testing. Standard sequencing reads short stretches of DNA and cannot always tell which chromosome a particular mutation came from. One reliable method is to test the parents: if one parent carries mutation A and the other carries mutation B, the child’s mutations must be in trans. Researchers have also proposed algorithms that can phase rare variants in family trios with nearly the same accuracy as knowing the true phase directly.³ When parental samples are unavailable, more specialized sequencing techniques, like long-read sequencing or targeted cDNA analysis, can sometimes resolve the question.

Getting this right has real clinical stakes. In pharmacogenomics, for instance, accurately assigning phase to variants in drug-metabolizing enzymes can change how a clinician predicts whether a patient will process a medication normally, slowly, or not at all.⁴

How Different Mutation Combos Shape Disease Severity

One of the most striking things about compound heterozygosity is that the specific pair of mutations a person carries can dramatically change how sick they get. Not all mutations are created equal. Some completely destroy a gene’s function (null or loss-of-function mutations), while others merely reduce it (hypomorphic mutations). When a person is compound heterozygous, the combination determines where they land on the severity spectrum.

A compelling example comes from a family with cystic fibrosis. Three siblings all inherited mutations in the CFTR gene from their parents, but in different combinations. Two siblings who received the I1234V variant paired with the 1677delTA variant developed classic, severe CF. The third sibling, who inherited I1234V paired with the milder L997F variant, had atypical CF with normal sweat test results and a much milder course. Their mother, who carried 1677delTA and L997F together, appeared completely healthy. The same variants produced entirely different outcomes depending on which partner mutation they were paired with.⁵

The same principle shows up in WARS2-related neurological disorders. Researchers found that a specific missense variant acts as a hypomorphic allele, meaning it still produces some functional protein. Individuals who are compound heterozygous for this hypomorphic allele alongside a loss-of-function variant on the other chromosome develop a milder form of the disease than those carrying two complete loss-of-function variants.⁶ This helps explain why the same genetic condition can range from devastating to manageable depending on the exact genotype.

In thalassemia, the blood disorder caused by defective hemoglobin genes, compound heterozygosity produces a full range of severity. Carrying two severe beta-zero thalassemia mutations together means no functional hemoglobin beta chains are produced at all, resulting in transfusion-dependent thalassemia major.⁷ But compound heterozygosity involving a “silent” beta-thalassemia mutation, one that barely affects the gene on its own, paired with a beta-zero mutation produces thalassemia intermedia, a moderate form that may not require regular transfusions.⁸

Compound Heterozygosity Does Not Always Mean Severe Disease

A common assumption is that losing function from both copies of a gene automatically leads to serious illness. Hemochromatosis, the iron-overload disorder linked to the HFE gene, shows this is not always true. People who are compound heterozygous for the two most common HFE mutations (C282Y and H63D) do tend to develop higher iron levels than the general population, but actual iron-overload disease is uncommon. In one large population-based study, only about one in 82 compound heterozygous men developed documented iron-overload-related disease, and none of the women did.⁹ This is a far cry from the picture many people have of hemochromatosis as an inevitable march toward liver damage.

The reasons vary by condition. Sometimes one of the two mutations is mild enough that the remaining partial gene function is adequate. Sometimes other genes, diet, or environmental factors compensate. The takeaway for anyone receiving genetic test results showing compound heterozygosity is that the label alone does not tell you how sick you will be; the specific mutations and the broader biological context matter enormously.

Compound Heterozygosity Versus Digenic Heterozygosity

Compound heterozygosity is sometimes confused with digenic heterozygosity, and the distinction matters. Compound heterozygous means two different mutations in the same gene on different chromosomes. Digenic heterozygous means mutations in two entirely different genes. In compound heterozygosity, one gene is knocked out. In digenic heterozygosity, two separate genes are each partially affected, and their combined effect causes disease.

Research on arrhythmogenic right ventricular cardiomyopathy (ARVC), a heart muscle disease, illustrates the overlap and the confusion. In a study of 38 patients with mutations in the PKP2 gene, nine carried compound heterozygous PKP2 variants (two different PKP2 mutations in trans). But 16 of those same 38 patients also carried mutations in a second, different desmosomal gene entirely, representing digenic heterozygosity.¹⁰ A Japanese study identified both patterns in their ARVC patients as well, finding cases with compound heterozygous mutations in DSG2 or PKP2, alongside a separate case of digenic heterozygosity involving PKP2 and DSG2 together.¹¹

From a patient’s perspective, the difference can change how genetic counselors assess risk for family members and which genes they screen. Compound heterozygosity follows classical recessive inheritance patterns, meaning both parents are carriers of variants in one specific gene. Digenic heterozygosity complicates that picture because the two contributing mutations may segregate independently through a family.

Hidden Mutations in Non-Coding Regions

Standard genetic testing typically focuses on exons, the portions of genes that directly code for protein. But some compound heterozygous cases involve one mutation in an exon and a second mutation buried deep inside an intron, the non-coding stretch between exons. These deep intronic variants are easy to miss because they do not show up on standard exome sequencing panels.

In Leigh syndrome, a severe neurological disorder, researchers identified siblings who were compound heterozygous for a known missense mutation in the NDUFAF6 gene and a deep intronic variant. The intronic change created a new splice site, causing the cell’s machinery to produce a garbled version of the protein. Only by analyzing the actual RNA transcripts could they prove the intronic variant was pathogenic.¹² A separate Leigh syndrome study found compound heterozygous intronic variants in a different gene, NDUFA3, that were also only detectable through whole genome sequencing combined with RNA analysis.¹³

In hypertrophic cardiomyopathy, a condition in which the heart muscle thickens abnormally, a patient was found to be compound heterozygous for a known splice-site mutation in one gene and a deep intronic variant in a different gene. Carriers of the splice-site mutation alone in the family were unaffected, but family members who were compound heterozygous showed clinical disease.¹⁴ These cases explain why some patients with clear clinical symptoms of a genetic disorder test “negative” on standard panels: the second hit is hiding in a place nobody looked.

When Two Broken Copies Partially Rescue Each Other

Here is where the genetics get counterintuitive. In some cases, carrying two different mutations actually produces more functional protein than carrying two copies of either mutation alone. This phenomenon is called intragenic complementation, and it happens when the protein in question works as a multimer, a complex assembled from multiple copies of itself.

If a protein functions as a pair or a larger assembly, a cell that makes two different mutant versions can sometimes mix and match them. One version might have a defect in one region while the other is damaged in a completely different region. When these two defective subunits combine, the functional regions of each can compensate for the damaged regions of the other, producing a partially working complex.

A large-scale study of the enzyme argininosuccinate lyase (ASL) tested thousands of compound heterozygous combinations of loss-of-function mutations in yeast. Over 60% of the combinations showed substantial enzyme activity, with growth levels between 56% and 110% of normal. Intragenic complementation was the rule rather than the exception, at least for active-site mutations in this enzyme.¹⁵ Earlier work on the enzyme propionyl-CoA carboxylase proposed a model for how this works: two differently mutated subunits, one damaged at the front end and one at the back end, can assemble into a complex where functional active sites are regenerated from the intact portions of each.¹⁶

Intragenic complementation helps explain some of the puzzling cases where patients with compound heterozygous mutations in a gene associated with severe disease turn out to be mildly affected or even asymptomatic. It is not just about whether each individual mutation is “severe” or “mild” on paper. The physical structure of the protein and how different damaged versions interact with each other also shape the outcome.

Rare Variants, Growing Populations, and Why This Pattern Is Getting More Attention

Compound heterozygosity becomes more relevant when rare mutations are involved, and rare mutations are more plentiful in large, rapidly growing populations. Modeling work has shown that rapid population growth increases the fraction of genetic variation that comes from rare alleles.¹⁷ In a small, stable population, a recessive disease gene tends to appear as one or two common mutations. In a large, recently expanded population, many different rare mutations circulate, making it far more likely that an affected individual inherits two different rare variants rather than two copies of the same one.

This is one reason compound heterozygosity was historically underappreciated. Early genetics research focused on isolated or founder populations where a single common mutation dominated. As sequencing spread to larger, more diverse populations, the same diseases kept appearing, but with different genetic architecture underneath. Cystic fibrosis is the textbook example: the F508del mutation accounts for roughly 70% of CF alleles in Northern European populations, but hundreds of rarer mutations exist worldwide, and many patients outside that demographic are compound heterozygous for two different rare variants rather than homozygous for F508del.

Gene Editing for Compound Heterozygous Conditions

Correcting a compound heterozygous genotype with gene editing poses a unique challenge: there are two different errors to fix, one on each chromosome. Researchers working on congenital erythropoietic porphyria, a rare blood disorder caused by compound heterozygous mutations in the UROS gene, tested two CRISPR strategies in patient-derived stem cells. One approach used a guide RNA that targeted both alleles. The other used a guide RNA specific to just one mutant allele. Both strategies successfully restored enzyme function. But the mutation-specific guide had a key advantage: it avoided damaging the opposite allele, which the biallelic guide sometimes did as collateral.¹⁸

This is still laboratory-stage work, but it highlights a design principle for future therapies: in compound heterozygous patients, you may only need to fix one of the two alleles to restore enough gene function. If the remaining allele has a mild (hypomorphic) mutation, correcting the more severe one could be sufficient. The therapy does not necessarily need to be twice as complex just because there are two different mutations.

What Carrier Screening Can and Cannot Catch

Modern expanded carrier screening panels test prospective parents for hundreds of recessive conditions at once. These panels are designed to flag heterozygous carriers, people who carry one broken copy of a gene without being affected. When both partners carry a variant in the same gene, the couple is at risk of having a compound heterozygous child.

But carrier screening is not foolproof. Panels typically look for known pathogenic variants and may miss rare or novel mutations, especially deep intronic ones as described above. In a large carrier screening cohort, researchers identified a small but meaningful number of individuals who were not just carriers but had compound heterozygous or otherwise pathogenic genotypes themselves, sometimes without knowing it.¹⁹ Some of these individuals had mild or subclinical forms of disease that had gone undiagnosed. Carrier screening is built to identify risk in future children, but occasionally it uncovers something about the person being tested.

For families already affected by a recessive condition, confirming compound heterozygosity (and ruling out the in-cis arrangement) guides reproductive counseling. If a child is confirmed compound heterozygous with mutations in trans, each parent is an obligate carrier, and each future pregnancy has a one-in-four chance of the same outcome. If the mutations turn out to be in cis, one parent carries both mutations on the same chromosome, the recurrence risk is different and the unaffected parent may not be a carrier at all.

Compound Heterozygosity in Cancer and Somatic Mutations

The concept extends beyond inherited disease. In cancer biology, a tumor cell sometimes acquires compound heterozygous inactivation of a tumor suppressor gene through a combination of an inherited germline mutation on one allele and a new somatic mutation on the other. This “two-hit” model was first proposed decades ago and remains central to understanding how tumor suppressors lose function.

In one documented case, a person who carried a germline deletion in the MEN1 tumor suppressor gene developed a brain tumor (a grade II astrocytoma) in which the second allele was also inactivated. The tumor represented a bi-allelic knockout of MEN1 that arose through compound heterozygous loss, mixing an inherited hit with a somatic one.²⁰ This case was unusual because MEN1-related tumors typically appear in endocrine organs, not the brain, expanding the known range of tissues where this gene matters.

Understanding compound heterozygosity in the somatic context is becoming more relevant as tumor sequencing becomes routine. When a cancer panel finds two different mutations in a known tumor suppressor, the same phasing question arises: are they in trans (both alleles knocked out, likely driving the tumor) or in cis (one allele knocked out, the other still functional, with the mutations possibly incidental)? Getting this wrong could mean misidentifying a driver gene or missing a therapeutic target.